State of Alaska Department of Revenue’s Acorda Therapeutics ACOR Stock Holding History

State of Alaska Department of Revenue’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-371	Closed	-$41K	–	1646
2020 Q1	$41K	Buy	371 +69	+23%	+$13.6K	﹤0.01%	1612
2019 Q4	$73K	Sell	302 -6	-2%	-$1.51K	﹤0.01%	1618
2019 Q3	$105K	Buy	308 +195	+173%	+$106K	﹤0.01%	1589
2019 Q2	$104K	Buy	113 +2	+2%	+$2.46K	﹤0.01%	1584
2019 Q1	$177K	Buy	111 +1	+0.9%	+$1.8K	﹤0.01%	1487
2018 Q4	$205K	Buy	110 +4	+4%	+$8.7K	﹤0.01%	1410
2018 Q3	$250K	Sell	106 -22	-17%	-$68.1K	﹤0.01%	1434
2018 Q2	$441K	Buy	128 +2	+2%	+$6.12K	0.01%	1156
2018 Q1	$358K	Buy	126 +48	+62%	+$144K	0.01%	1145
2017 Q4	$199K	Buy	78 +1	+1%	+$2.84K	﹤0.01%	1273
2017 Q3	$218K	Hold	77	–	–	0.01%	980
2017 Q2	$181K	Buy	77 +34	+79%	+$67.4K	0.01%	915
2017 Q1	$107K	Buy	43 +1	+2%	+$2.88K	0.01%	924
2016 Q4	$93K	Buy	+42	New	+$99.9K	0.01%	681

Other funds holding ACOR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State of Alaska Department of Revenue's ACOR Position: Q2 2020 in Review

State of Alaska Department of Revenue sold out of Acorda Therapeutics (ACOR) in Q2 2020, closing a stake of 371 shares — an estimated $41K sold.

State of Alaska Department of Revenue first reported a position in ACOR in Q4 2016 and held it in 14 quarters. The position peaked at $441K in Q2 2018. 79 funds tracked by Wall St. Rank hold ACOR as of Q2 2020.

State of Alaska Department of Revenue reported no remaining Acorda Therapeutics position as of Q2 2020 after selling out during the quarter.
State of Alaska Department of Revenue sold 371 Acorda Therapeutics shares in Q2 2020, an estimated $41K.
State of Alaska Department of Revenue first reported a position in Acorda Therapeutics in Q4 2016 and held it in 14 quarters.
State of Alaska Department of Revenue's Acorda Therapeutics position peaked at $441K in Q2 2018.
79 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2020.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2020, filed 6 Jul 2020.